Ligand Pharmaceuticals Incorporated (LGND)

Ligand Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	55.96	174.93	72.31	22.95	45.01	19.52
Short-Term Investments	391.44	558.59	183.86	147.36	166.86	321.59
Cash & Short-Term Investments	447.4	733.52	256.17	170.31	211.87	341.11
Cash Growth	-32.67%	186.35%	50.41%	-19.62%	-37.89%	-17.04%
Accounts Receivable	110.72	82.39	48.4	32.92	30.42	85.45
Other Receivables	24.3	1.45	4.07	6.4	4.61	6.19
Receivables	135.01	83.84	52.47	39.31	35.04	91.65
Inventory	14.51	9.13	14.11	23.97	13.29	27.33
Prepaid Expenses	-	-	-	1.18	1.13	-
Restricted Cash	4.11	-	-	-	-	-
Other Current Assets	7.21	5.79	8.81	2.66	2.27	4.67
Total Current Assets	608.23	832.27	331.56	237.43	263.6	464.75
Property, Plant & Equipment	20.51	7.22	9.67	25.06	27.49	32.6
Long-Term Investments	142.92	167.95	10.91	49.32	3	-
Goodwill	207.86	101.54	105.25	103.37	105.67	105.67
Other Intangible Assets	302.04	225.44	266.65	299.61	352.64	386.8
Long-Term Accounts Receivable	772.62	196.88	185.02	62.29	-	-
Long-Term Deferred Tax Assets	104.12	8.35	0.07	0.21	8.53	35.73
Other Long-Term Assets	79.16	20.99	32.64	9.92	1.74	272.03
Total Assets	2,237	1,561	941.77	787.22	762.67	1,298

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	4.09	3.24	5.23	2.43	5.31	8.4
Accrued Expenses	33.29	29.08	25.53	10.09	13.3	12.4
Current Portion of Long-Term Debt	448.31	-	-	-	76.7	-
Current Portion of Leases	4.56	1.12	1.29	0.41	0.72	1.41
Current Income Taxes Payable	2.75	1.24	1.2	-	-	-
Current Unearned Revenue	-	-	-	1.22	0.36	0.65
Other Current Liabilities	7.58	2.78	3.86	2.63	2.43	18.8
Total Current Liabilities	500.57	37.45	37.11	16.78	98.81	41.67
Long-Term Debt	679.91	446.19	-	-	-	320.72
Long-Term Leases	21.43	4.23	5.86	5.77	10.34	2.31
Long-Term Unearned Revenue	-	-	18.18	15.14	0.04	-
Long-Term Deferred Tax Liabilities	22.4	36.02	32.52	31.62	30.62	30.86
Other Long-Term Liabilities	51.39	19.54	17.65	16.98	25.37	80.88
Total Liabilities	1,276	543.43	111.34	86.3	165.18	476.43

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0.02	0.02	0.02	0.02	0.02	0.02
Additional Paid-In Capital	403.54	400.65	337.38	198.7	147.59	372.97
Retained Earnings	554.77	608.09	498.98	503.02	450.86	449.09
Comprehensive Income & Other	3.44	8.46	-5.94	-0.82	-0.98	-0.92
Shareholders' Equity	961.76	1,017	830.44	700.91	597.49	821.16
Total Liabilities & Equity	2,237	1,561	941.77	787.22	762.67	1,298

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	1,154	451.54	7.15	6.18	87.75	324.44
Net Cash (Debt)	-706.81	281.98	249.01	164.13	124.12	16.66
Net Cash Growth	-	13.24%	51.72%	32.23%	644.83%	-
Net Cash Per Share	-32.82	13.89	13.61	9.24	7.36	0.97
Filing Date Shares Outstanding	20	19.94	19.26	17.71	17.08	16.85
Total Common Shares Outstanding	20	19.77	19.11	17.56	16.95	16.77
Working Capital	107.67	794.82	294.45	220.65	164.79	423.09
Book Value Per Share	48.09	51.44	43.46	39.92	35.25	48.97
Tangible Book Value	451.86	690.23	458.54	297.94	139.18	328.69
Tangible Book Value Per Share	22.59	34.91	24.00	16.97	8.21	19.60
Machinery	-	-	-	7.78	15.16	14.34
Construction In Progress	-	-	-	4.12	-	-
Leasehold Improvements	-	-	-	10.36	7.45	5.27

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Oct 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 4, 2026

Data Sources Report a data error